Medina Manuel Hidalgo Sells 1,000 Shares of Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH) Director Medina Manuel Hidalgo sold 1,000 shares of Guardant Health stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $130.06, for a total value of $130,060.00. Following the transaction, the director owned 639 shares of the company’s stock, valued at $83,108.34. This trade represents a 61.01% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Medina Manuel Hidalgo also recently made the following trade(s):

• On Wednesday, May 20th, Medina Manuel Hidalgo sold 1,250 shares of Guardant Health stock. The shares were sold at an average price of $107.09, for a total value of $133,862.50.
• On Friday, March 6th, Medina Manuel Hidalgo sold 1,300 shares of Guardant Health stock. The shares were sold at an average price of $91.54, for a total value of $119,002.00.

Guardant Health Stock Performance

GH stock opened at $129.69 on Friday. Guardant Health, Inc. has a 52-week low of $38.03 and a 52-week high of $133.97. The business has a 50-day simple moving average of $95.08 and a two-hundred day simple moving average of $99.94. The company has a market capitalization of $17.20 billion, a P/E ratio of -38.26 and a beta of 1.48.

Analysts Set New Price Targets

GH has been the topic of a number of research analyst reports. Barclays boosted their target price on Guardant Health from $115.00 to $120.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Stifel Nicolaus boosted their target price on Guardant Health from $120.00 to $130.00 and gave the stock a “buy” rating in a research note on Friday, February 20th. JPMorgan Chase & Co. boosted their target price on Guardant Health from $130.00 to $135.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Guardant Health in a research note on Tuesday, April 21st. Finally, Citigroup boosted their target price on Guardant Health from $135.00 to $150.00 and gave the stock a “buy” rating in a research note on Friday, February 20th. Nineteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Guardant Health presently has a consensus rating of “Moderate Buy” and an average target price of $129.79.

Institutional Investors Weigh In On Guardant Health

Hedge funds have recently modified their holdings of the stock. V Square Quantitative Management LLC bought a new stake in shares of Guardant Health in the 4th quarter worth approximately $27,000. Chesapeake Asset Management LLC bought a new stake in shares of Guardant Health in the 4th quarter worth approximately $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Guardant Health in the 4th quarter worth approximately $31,000. Elyxium Wealth LLC bought a new stake in shares of Guardant Health in the 4th quarter worth approximately $35,000. Finally, Parallel Advisors LLC raised its holdings in shares of Guardant Health by 164.7% in the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after purchasing an additional 219 shares during the period. Institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.